The Economist asks:
Will the US FDA approve the drug molnupiravir for use to treat COVID-19 before 1 October 2021?
Molnupiravir, a drug being developed by Merck and Ridgeback Biotherapeutics, has shown positive results in clinical trials in combatting COVID-19 (Economist, Fox News, Merck). “Compassionate use" and "emergency use" authorizations would count (FDA, FDA).
NOTE 3 August 2021: FDA approval for molnupiravir for use in combination with other therapeutics to treat COVID-19 would count.
The question closed "No" with a closing date of 1 October 2021.